LIPID CONTROL AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI) IN CHINA

被引：0
|
作者：
Wei, M. [1 ]
Sun, Y. [2 ]
Liu, G. [3 ]
Hei, Y. [4 ]
Zhao, Z. [4 ]
机构：
[1] 6th Peoples Hosp Shanghai, Shanghai, Peoples R China
[2] Peking Univ, Beijing 100871, Peoples R China
[3] Peking Univ, Guanghua Sch Management, Beijing 100871, Peoples R China
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.279
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV54
引用
收藏
页码：A764 / A764
页数：1
相关论文
共 50 条
  • [41] Intracoronary laser photoremodeling (LP). The new method in restenosis prevention after percutaneous coronary intervention (PCI)
    Derkacz, A
    Bialy, D
    Protasicwicz, M
    Abramski, K
    Pawlik, E
    Arkowski, J
    Nowosad, H
    FRONTIERS IN CORONARY ARTERY DISEASE, 2003, : 657 - 660
  • [42] Assessment of clinical outcomes related to early discharge after elective percutaneous coronary intervention: COED PCI
    Muthusamy, Purushothaman
    Busman, Denise K.
    Davis, Alan T.
    Wohns, David H.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2013, 81 (01) : 6 - 13
  • [43] Virtual 3 Fr PCI system for complex percutaneous coronary intervention
    Matsukage, Takashi
    Yoshimachi, Fuminobu
    Masutani, Motomaru
    Saito, Shigeru
    Nakazawa, Gaku
    Masuda, Naoki
    Ogata, Nobuhiko
    Morino, Yoshihiro
    Ikari, Yuji
    EUROINTERVENTION, 2009, 5 (04) : 515 - 517
  • [44] Use of abciximab in patients undergoing percutaneous coronary intervention (PCI) in France
    Fillon, F
    Macé, J
    Chemali, N
    De Kervasdoué, J
    VALUE IN HEALTH, 2005, 8 (06) : A99 - A99
  • [45] Assessment of Equity in Access to Percutaneous Coronary Intervention (PCI) Centres in Poland
    Roj, Justyna
    Jankowiak, Maciej
    HEALTHCARE, 2020, 8 (02)
  • [46] An audit of prescribing of abciximab (Reopro®) during percutaneous coronary intervention (PCI)
    Patel, P.
    Williams, H.
    Chapman, S.
    PHARMACY WORLD & SCIENCE, 2008, 30 (03): : 307 - 308
  • [47] The Hypercholesterolemia Paradox in Percutaneous Coronary Intervention: An Analysis of a Multicenter PCI Registry
    Ueshima, Daisuke
    Yoshikawa, Shunji
    Sasaoka, Taro
    Hatano, Yu
    Kurihara, Ken
    Maejima, Yasuhiro
    Isobe, Mitsuaki
    Ashikaga, Takashi
    INTERNAL MEDICINE, 2019, 58 (03) : 345 - 353
  • [48] EFFECT OF THROMBOLYTIC THERAPY AND PERCUTANEOUS CORONARY INTERVENTION (PCI) ON INFLAMMATORY MEDIATORS
    Bagheri, B.
    Garjani, A.
    Taherkhanchi, B.
    Sohrabi, B.
    Mousavi, F.
    ATHEROSCLEROSIS, 2016, 252 : E183 - E183
  • [49] Is there a role for BivaliRUdin in Transradial Percutaneous Coronary Intervention? - The BRUT PCI Study
    Adusumalli, Sundeep
    Harris, Gregory
    Chagarlamudi, Arjun
    Nash, Gary M.
    Siddiqui, Adeel
    Paladugu, Nikhil
    Daggubati, Ramesh B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B97 - B97
  • [50] Nationwide trends in the utilization of percutaneous coronary intervention (PCI) in the United States
    Movahed, M. R.
    Hashemzadeh, M.
    Jamal, M. M.
    CIRCULATION, 2008, 118 (12) : E486 - E486
12345